Report: Biotech licensing, M&A deals dropped in 2012

04/1/2013 | Genetic Engineering & Biotechnology News

Biotech and biopharmaceutical firms struck fewer licensing and acquisition deals in 2012 compared with 2011, perhaps fueled by greater confidence in drug pipelines and fewer worries about patent expirations, according to a new report from EP Vantage. Total licensing-deal value declined 19%, to $20.9 billion, and the number of products licensed dropped from 1,037, to 759. Merger and acquisition deals reached $42.6 billion, down 24%.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC